BIOTRONIK is reporting that its new Lumax 540 implantable cardioverter defibrillator (ICD) and cardiac resynchronization therapy defibrillator (CRT-D) has been implanted in a number of patients in the European Union. The device has been granted CE Mark of approval about two weeks ago. One of the features that BIOTRONIK is particularly proud of is the ability of this device to provide continuous wireless home monitoring for cardiac patients:
The new Lumax 540 platform is part of BIOTRONIK´s most technologically advanced tachycardia product portfolio, providing extended therapy options- for individualized patient device programming as well as BIOTRONIK Home Monitoring® technology for wireless remote monitoring of patient’s cardiovascular status.
A comprehensive set of diagnostic capabilities are further technical advancements included on the Lumax 540 devices to help physicians identify clinically relevant atrial fibrillation and early detection of worsening heart failure status.
Due to the advantage of developing its own industry-leading batteries and years of engineering research, BIOTRONIK has achieved longevity for the Lumax 540 platform which extends the life of the devices up to 10 years. “Patients could benefit from this extended battery longevity due to the need for fewer device replacements over time, thereby improving quality of life and at the same time helping to reduce healthcare costs”, commented Marlou Janssen, Vice President Global Marketing and Sales, Cardiac Rhythm Management, BIOTRONIK. “In fact, we are so confident in the advantages of our new battery technology, BIOTRONIK will further extend our warranty for the Lumax 540 ICDs.”
In response to the increasing number of implanted cardiac devices, technologies which ease complex programming, enable remote monitoring and simplify patient follow-up have become increasingly important. Therefore, Lumax 540 series was specifically designed to improve effective tachyarrhythmia programming and facilitate patient follow-up with an innovative set of functionalities that help physicians efficiently automate the in-office follow-up of patients with BIOTRONIK devices.
Furthermore, in combination with BIOTRONIK Home Monitoring® technology, the new Lumax 540 platform sets the standard for remote monitoring of patients with cardiac devices. This exclusive technology enables continuous automatic daily data transmissions of the patient’s cardiovascular status and clinically significant events to the physician from anywhere in the world using an antenna integrated in the Lumax 540 devices and the mobile telephone network…
Lumax 540 devices offer the unique combination of advanced tachycardia therapy management, diagnostic capabilities and remote monitoring technologies which support physicians in creating efficient care pathways for their patients with cardiac devices and further improve patient care.
In response to the increasing number of implanted cardiac devices, technologies which ease complex programming, enable remote monitoring and simplify patient follow-up have become increasingly important. Therefore, Lumax 540 series was specifically designed to improve effective tachyarrhythmia programming and facilitate patient follow-up with an innovative set of functionalities that help physicians efficiently automate the in-office follow-up of patients with BIOTRONIK devices.Press release: BIOTRONIK Announces First Implants of Lumax 540 Series…